Eczema Creams Finally Merit Cancer Labeling
February 07 2006
|
4,128
views
The FDA has announced that two prescription eczema creams will need to bear "black box" warnings of possible cancer risks. The creams, Elidel and Protopic, are now recommended for use only after other prescription medications have failed.
There have been nearly 80 reported cases of cancer in patients treated with the two drugs. Novartis Pharmaceuticals, which manufactures Elidel, announced that it is still confident in the safety and efficacy of Elidel.
In addition to the reported cancer cases, animal tests show an increase in cancer risk associated with the drugs.